XML 32 R19.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2021202020212020
Novartis Institutes for BioMedical Research, Inc.40 %— %35 %— %
Biogen MA, Inc.38 %16 %39 %19 %
Kite Pharma, Inc.22 %13 %23 %24 %
Sanofi S.A.(3)%3 %2 %4 %
Pfizer Inc.— 68 %— 51 %
Schedule of Cash and Cash Equivalents A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):
September 30,
2021		December 31,
2020		September 30,
2020		December 31,
2019
Cash and cash equivalents$176,954 $131,329 $259,393 $80,428 
Non-current restricted cash1,500 1,500 1,500 1,500 
Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows$178,454 $132,829 $260,893 $81,928 
Restrictions on Cash and Cash Equivalents A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):
September 30,
2021		December 31,
2020		September 30,
2020		December 31,
2019
Cash and cash equivalents$176,954 $131,329 $259,393 $80,428 
Non-current restricted cash1,500 1,500 1,500 1,500 
Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows$178,454 $132,829 $260,893 $81,928